Transcode Therapeutics (RNAZ) Share-based Compensation (2020 - 2026)

Transcode Therapeutics (RNAZ) has reported Share-based Compensation for 7 consecutive years, with $2035.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Share-based Compensation changed 0.2% year-over-year to $2035.0; the trailing twelve-month figure through Jun 2026 stood at $2035.0 (changed 0.2% YoY), and the FY2025 full-year result was $485428.0, down 71.45% from the prior year.
• Share-based Compensation was little changed at $2035.0 in Q2 2026 per RNAZ's latest filing, from $2035.0 in the prior quarter.
• Across five years, Share-based Compensation topped out at $3.0 million in Q1 2023 and bottomed at $2035.0 in Q1 2026.
• Historically, Share-based Compensation has averaged $835351.6 across 5 years, with a median of $225214.5 in 2023.
• The sharpest annual moves came in 2022 and 2025: Share-based Compensation soared 4223.75% in 2022, then sank 99.89% in 2025.
• Over 5 years, Share-based Compensation stood at $130555.0 in 2022, then surged by 137.69% to $310314.0 in 2023, then tumbled by 45.61% to $168770.0 in 2024, then slumped by 63.34% to $61865.0 in 2025, then plunged by 96.71% to $2035.0 in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $2035.0, $2035.0, and $61865.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.